UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AML-592 Treatment of Acute Myeloid Leukemia With Venetoclax-Based Combinations in Argentina: A Real-World Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S323-S324

2024

Volltextzugriff (PDF)

Ven the dose matters: Venetoclax dosing in the frontline treatment of AML

Blood reviews, 2024-08, p.101238, Article 101238

2024

Volltextzugriff (PDF)

MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S357-S358

2023

Volltextzugriff (PDF)

AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S277-S277

2023

Volltextzugriff (PDF)

AML-308 Real-World (RW) Outcomes With Venetoclax (VEN) in Patients With Acute Myeloid Leukemia (AML) From COTA, a US RW Evidence Database

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S288-S289

2023

Volltextzugriff (PDF)

CLL-347 Venetoclax Therapy in Chronic Lymphocytic Leukemia Patients Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S325-S326

2023

Volltextzugriff (PDF)

AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S285-S286

2023

Volltextzugriff (PDF)

Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax

Biochemical pharmacology, 2024-10, Vol.228, p.116065, Article 116065

2024

Volltextzugriff (PDF)

AML-522 Outcomes of Patients Treated With Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms; Real World Data from a Single Center Cohort

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S259

2022

Volltextzugriff (PDF)

AML-032 Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S289-S289

2024

Volltextzugriff (PDF)

AML-700 Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S332-S332

2024

Volltextzugriff (PDF)

MCL-229 Using the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S514-S514

2024

Volltextzugriff (PDF)

Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S92-S94

2024

Volltextzugriff (PDF)

EXABS-178-AML Venetoclax-Based Triplet Regimens in AML

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S77-S78

2023

Volltextzugriff (PDF)

Venetoclax: evidence to date and clinical potential

Drugs in Context, 2019-10, Vol.8, p.1-13

2019

Volltextzugriff (PDF)

Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets

Clinical therapeutics, 2024-05

2024

Volltextzugriff (PDF)

The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia

Leukemia & lymphoma, 2021-05, Vol.62 (6), p.1466-1473

2021

Volltextzugriff (PDF)

BCL-2 Inhibition in MDS

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S104-S106

Wei, Andrew H.

2021

Volltextzugriff (PDF)

AML-327: Plasmacytoid Dendritic Cell Proliferation Associated with Acute Myeloid Leukemia: A Case Report

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S306-S306

2021

Volltextzugriff (PDF)

AML-212: Treatment Free Remission (TFR) After Ceasing Venetoclax-Based Therapy in Responding Patients with Acute Myeloid Leukemia

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S291-S292

2021

Volltextzugriff (PDF)

MDS-128: Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S341-S341

2021

Volltextzugriff (PDF)

AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S282-S283

2023

Volltextzugriff (PDF)

AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S293-S294

2023

Volltextzugriff (PDF)

AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S303-S303

2023

Volltextzugriff (PDF)

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature

Hematology/oncology and stem cell therapy, 2021-09, Vol.14 (3), p.246-251

2021

Volltextzugriff (PDF)

1 – 25 von 1.566

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.157)
Mit Volltextzugriff
(1.030)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Venetoclax
(1.509)
Science & Technology
(971)
Life Sciences & Biomedicine
(960)
Oncology
(552)
Humans
(479)
Hematology
(430)
Leukemia
(383)
Acute Myeloid Leukemia
(375)
Chronic Lymphocytic Leukemia
(245)
Chemotherapy
(239)
Apoptosis
(232)
Patients
(209)
Cancer
(203)
Ibrutinib
(193)
Leukemia, Myeloid, Acute - Drug Therapy
(162)
Aml
(155)
Bridged Bicyclo Compounds, Heterocyclic - Therapeutic Use
(147)
Clinical Trials
(142)
Pharmacology & Pharmacy
(142)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(124)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(54)
... seit 30 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

AML-592 Treatment of Acute Myeloid Leukemia With Venetoclax-Based Combinations in Argentina: A Real-World Study

Ven the dose matters: Venetoclax dosing in the frontline treatment of AML

MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation

AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

AML-308 Real-World (RW) Outcomes With Venetoclax (VEN) in Patients With Acute Myeloid Leukemia (AML) From COTA, a US RW Evidence Database

CLL-347 Venetoclax Therapy in Chronic Lymphocytic Leukemia Patients Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting

Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax

AML-522 Outcomes of Patients Treated With Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms; Real World Data from a Single Center Cohort

AML-032 Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

AML-700 Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB

MCL-229 Using the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma

Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms

EXABS-178-AML Venetoclax-Based Triplet Regimens in AML

Venetoclax: evidence to date and clinical potential

Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets

The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia

BCL-2 Inhibition in MDS

AML-327: Plasmacytoid Dendritic Cell Proliferation Associated with Acute Myeloid Leukemia: A Case Report

AML-212: Treatment Free Remission (TFR) After Ceasing Venetoclax-Based Therapy in Responding Patients with Acute Myeloid Leukemia

MDS-128: Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes

AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML

AML-377 Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations

AML-454 Real-World Use of Azacitidine (AZA) and Venetoclax (VEN) in Acute Myeloid Leukemia (AML) in Frontline and Relapse/Refractory (R/R) Settings: Multicenter Study From French AURAML Group

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature

Suchergebnisse filtern